Patents by Inventor Samuel H. Gellman

Samuel H. Gellman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10543255
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: January 28, 2020
    Assignee: LONGEVITY BIOTECH, INC.
    Inventors: Scott Shandler, Samuel H. Gellman, John M. Gledhill
  • Patent number: 10501518
    Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include at least two non-adjacent ?-amino acid residues in place of a naturally occurring ?-amino acid residues. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: December 10, 2019
    Assignees: Wisconsin Alumni Research Foundation, General Hospital Corporation
    Inventors: Samuel H. Gellman, Ross W. Cheloha, Thomas J. Gardella
  • Patent number: 10463688
    Abstract: A method and corresponding composition to inhibit outgrowth of C. difficile spores and/or to inhibit growth of C. difficile vegetative cells in a mammal in which an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof is administered to the subject.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: November 5, 2019
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Samuel H. Gellman, Runhui Liu, Bernard Weisblum, Shonna M. McBride
  • Patent number: 10323121
    Abstract: Disclosed is a method of making ?-polypeptides. The method includes polymerizing ?-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product ?-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
    Type: Grant
    Filed: May 15, 2017
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Shannon S. Stahl, Samuel H. Gellman, Sarah E. Lee, Mehmet F. Ilker, Bernard Weisblum, Denis Kissounko
  • Patent number: 10322998
    Abstract: Disclosed are isolated, unnatural polypeptides containing cyclically-constrained ?-amino acid residues and cyclically-constrained ?-amino acid residues. The compounds are unnatural and because they contain rotationally constrained residues that are not amenable to enzymatic degradation, the compounds are useful to probe protein-protein and other large molecule interactions.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: June 18, 2019
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Samuel H. Gellman, Ahlke Hayen, Margaret A. Schmitt, Felix N. Ngassa
  • Publication number: 20190062397
    Abstract: Described are polypeptide analogs of parathyroid hormone (PTH) that include an unnatural amino acid substitution at positions 7 or 8 from the N-terminus of the polypeptide. Also described are pharmaceutical compositions useful for treating hypoparathyroidism that contain the analogs and methods of using the analogs to treat hypoparathyroidism.
    Type: Application
    Filed: August 22, 2018
    Publication date: February 28, 2019
    Inventors: Samuel H. Gellman, Shi Liu
  • Publication number: 20180193423
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Application
    Filed: September 19, 2017
    Publication date: July 12, 2018
    Inventors: Scott Shandler, Samuel H. Gellman, John M. Gledhill
  • Publication number: 20180193422
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Application
    Filed: August 31, 2017
    Publication date: July 12, 2018
    Inventors: Scott J. Shandler, Samuel H. Gellman
  • Publication number: 20180153928
    Abstract: Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of ?-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.
    Type: Application
    Filed: February 5, 2018
    Publication date: June 7, 2018
    Applicants: WISCONSIN ALUMNI RESEARCH FOUNDATION, NORTHWESTERN UNIVERSITY
    Inventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
  • Patent number: 9925213
    Abstract: Non-natural oligomers have recently shown promise as functional analogs of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of ?-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: March 27, 2018
    Assignees: WISCONSIN ALUMNI RESEARCH FOUNDATION, NORTHWESTERN UNIVERSITY
    Inventors: Samuel H. Gellman, Shannon S. Stahl, Brendan P. Mowery, Annelise Barron, Michelle Dohm
  • Publication number: 20170320928
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 9, 2017
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian
  • Patent number: 9790262
    Abstract: This invention relates to novel compositions comprising analogs of glucagon, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways, including diabetes and other metabolic disorders. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: October 17, 2017
    Assignee: LONGEVITY BIOTECH, INC.
    Inventors: Scott Shandler, Samuel H. Gellman
  • Patent number: 9789164
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: October 17, 2017
    Assignee: LONGEVITY BIOTECH, INC.
    Inventors: Scott Shandler, Samuel H. Gellman, John M. Gledhill
  • Patent number: 9782454
    Abstract: This invention relates to novel compositions comprising analogs of naturally occurring polypeptides, wherein the analog comprises an ?-amino acid and at least one ?-amino acid. Administration of the compositions may be used for effecting treatment or prevention of a plurality of disease states caused by dysfunctional biochemical or biological pathways. The compositions and methods of this invention are particularly useful to identify novel therapeutic modulators of in-vivo receptor activity with extended half-lives and relevant bioactivity as compared to the naturally translated polypeptides upon which the analogs are derived.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: October 10, 2017
    Assignee: LONGEVITY BIOTECH, INC.
    Inventors: Scott J. Shandler, Samuel H. Gellman
  • Publication number: 20170247510
    Abstract: Disclosed is a method of making ?-polypeptides. The method includes polymerizing ?-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product ?-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
    Type: Application
    Filed: May 15, 2017
    Publication date: August 31, 2017
    Inventors: Shannon S. Stahl, Samuel H Gellman, Sarah E Lee, Mehmet F Ilker, Bernard Weisblum, Denis Kissounko
  • Patent number: 9738697
    Abstract: Described herein are peptide analogs of glucagon-like peptide 1 (GLP-1) that retain agonist activity, but are more resistant to proteolytic degradation than native GLP-1. In the analogs, at least one ?-amino acid found in the native GLP-1 is replaced with a ?-amino acid residue, which may or may not be cyclically constrained. Pharmaceutical compositions containing the analogs are described, as are methods to treat diabetes, and methods to make proteolytically resistant GLP-1 analogs.
    Type: Grant
    Filed: June 23, 2014
    Date of Patent: August 22, 2017
    Assignees: Wisconsin Alumni Research Foundation, President and Fellows Of Harvard College
    Inventors: Samuel H. Gellman, Lisa M. Johnson, Alan Attie, Mark P. Keller, Alan Saghatelian
  • Patent number: 9683081
    Abstract: Disclosed is a method of making ?-polypeptides. The method includes polymerizing ?-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product ?-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 20, 2017
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Shannon S. Stahl, Samuel H. Gellman, Sarah E. Lee, Mehmet F. Ilker, Bernard Weisblum, Denis Kissounko
  • Publication number: 20170000818
    Abstract: A method and corresponding composition to inhibit outgrowth of C. difficile spores and/or to inhibit growth of C. difficile vegetative cells in a mammal in which an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof is administered to the subject.
    Type: Application
    Filed: June 30, 2016
    Publication date: January 5, 2017
    Inventors: Samuel H. Gellman, Runhui Liu, Bernard Weisblum, Shonna M. McBride
  • Patent number: 9416156
    Abstract: Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising ?-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the ?-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with ?-amino acid residues, and the ?-amino acid residues are distributed in a repeating pattern.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: August 16, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: William S. Horne, Samuel H. Gellman, Lisa M. Johnson
  • Patent number: 9370534
    Abstract: Pharmaceutical compositions containing biocidal co-polymers of poly(styrenes), poly(acrylates), poly(acrylamides), and poly(C1-C6)alkylene glycols are disclosed, along with methods of using the compositions to treat microbial infections in mammals.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: June 21, 2016
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Samuel H. Gellman, Michael A. Gelman, Bernard Weisblum, David M. Lynn